Prospective Grant of an Exclusive Patent License: The Development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Mesothelin-Expressing Human Cancers
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Evotec International GmbH (Evotec), located in Hamburg, Germany.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.